NCT04617054View on ClinicalTrials.gov

Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2026

Conditions
Solid Tumor
Interventions
DRUG

AB-106

600mg QD for each subjects.

Trial Locations (1)

Unknown

RECRUITING

Chinese PLA General Hospital, Beijing

Sponsors
All Listed Sponsors
lead

AnHeart Therapeutics Inc.

INDUSTRY